Morning Trend | EVEREST MED tests with reduced volume, is an opportunity in the pharmaceutical defensive sector approaching?
Yesterday, EVEREST MED's daily line once again retreated, with a continued tug-of-war at new lows, and the main funds remained cautiously on the sidelines. The pharmaceutical sector has been performing very poorly lately, with the market being particularly sensitive to the launch of new drugs and valuation corrections within the sector, and sentiment has not seen significant recovery. Stock prices continue to consolidate at low levels, with the 5-day and 10-day moving averages declining simultaneously, and trading activity is noticeably insufficient. It is worth mentioning that recent media reports have indicated that the domestic innovative drug application green channel has been further strengthened, with some leading companies obtaining new drug approvals, but local pharmaceutical stocks have generally reacted flatly. The market interprets this as an intensification of the wait-and-see atmosphere, with funds quickly flowing out after a brief period of attention, indicating that while the pharmaceutical sector has defensive attributes, its attractiveness is limited. Technically, the MACD remains negative, with occasional tentative fund boosts during the session but lacking sustainability. Overall, EVEREST MED shows no signs of breakthrough, and short-term risk exposure cannot be ignored. Investors should continue to track changes in trading volume and policy developments, paying attention to intraday volatility opportunities brought by sudden news. From the overall performance of the pharmaceutical sector, this field continues to bear the brunt of market sentiment lows, with investors primarily adopting defensive allocations. Currently, the downward channel for EVEREST MED has not yet ended, and a significant rebound in the future is expected to require either major external positive stimuli or appropriate valuation adjustments. In the absence of trend reversal signals, the operational suggestion is to prioritize risk control and adopt a wait-and-see approach
Yesterday, EVEREST MED's daily line once again retreated, with a continued tug-of-war at new lows, and the main funds remained cautiously withdrawn. The pharmaceutical sector has recently performed very poorly, with the market being particularly sensitive to the launch of new drugs and valuation adjustments within the sector, and sentiment has not seen significant recovery. Stock prices continue to consolidate at low levels, with the 5-day and 10-day moving averages declining simultaneously, and trading activity is noticeably insufficient.
It is worth mentioning that recent media reports have indicated that the domestic innovative drug application green channel has been further strengthened, with some leading companies obtaining new drug approvals, but local pharmaceutical stocks have generally reacted blandly. The market interprets this as an intensification of the wait-and-see atmosphere, with funds quickly flowing out after a brief focus, indicating that while the pharmaceutical sector has defensive attributes, its attractiveness is limited. Technically, the MACD remains negative, and there are occasional attempts at upward movement during the day, but the sustainability is insufficient.
Overall, EVEREST MED shows no signs of breakthrough, and short-term risk exposure cannot be ignored. Investors should continue to track changes in trading volume and policy trends, paying attention to intraday volatility opportunities brought about by sudden news. From the overall performance of the pharmaceutical sector, this field continues to bear the brunt of market sentiment lows, with investors primarily adopting defensive allocations. Currently, EVEREST MED's downward channel has not yet ended, and a significant rebound in the future is expected to require external major positive stimuli or appropriate valuation adjustments. In the absence of trend reversal signals, the operational suggestion is to prioritize risk control and adopt a wait-and-see approach
